ArticleClinical and experimental medicine2026
Identifying coagulation-related biomarkers in steroid-induced osteonecrosis of the femoral head: implications for early diagnosis and treatment.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-induced osteonecrosis of the femoral head (SONFH) is closely associated with coagulation dysfunction, but its molecular mechanisms remain incompletely understood. This study aimed to identify coagulation-related biomarkers for SONFH and evaluate their diagnostic relevance. The GSE123568 dataset from the Gene Expression Omnibus database (GEO) was analyzed, and differentially expressed genes (DEGs) were intersected with coagulation-related genes (CRGs) from the Molecular Signatures Database to identify coagulation-related differentially expressed genes (CRDEGs). Functional enrichment analysis was performed to explore the biological processes and pathways associated with these genes, while protein-protein interaction network analysis and three machine learning algorithms were applied to identify key genes. A nomogram model was constructed and evaluated using bootstrap internal validation. Gene set enrichment analysis, single-sample gene set enrichment analysis, competing endogenous RNA network, and Drug Signature Database analyses were performed to explore potential regulatory mechanisms. The expression levels of the key genes were preliminarily assessed by reverse transcription quantitative polymerase chain reaction (RT-qPCR). In total, 49 CRDEGs were identified and were mainly enriched in immune response, blood coagulation, and complement and coagulation cascades. PECAM1, LGALS3, and ANXA5 were identified as key genes. The prediction model constructed based on these genes showed favorable diagnostic discrimination, with a bootstrap AUC of 0.939 (95% CI: 0.840-0.977). RT-qPCR showed decreased PECAM1 and LGALS3 expression and increased ANXA5 expression in SONFH patients. These findings suggest that PECAM1, LGALS3, and ANXA5 may serve as potential coagulation-related biomarkers for SONFH, providing a basis for further clinical validation and mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.